Objective: The aim of the present retrospective analysis was to determine the effectiveness of pelvic radiotherapy (RT) as postoperative adjuvant therapy for low-risk cervical cancer. 
Introduction
Cervical cancer is a malignancy tumor in gynecology which does great harm to women's health, and gradually becomes the third most commonly diagnosed cancer and the fourth leading cause of cancer death in females worldwide (1) . Patients with International Federation of Gynecology and Obstetrics (FIGO) Stage IB1-IIA cervical cancer has a relatively favorable prognosis whatever undergoing surgical treatment or radiotherapy, with an about 87% 5-year survival rate (2), the 3-year survival rate can even be up to 100% (3) . Low-risk (being defined as negative pelvic lymph nodes and surgical margin, without parametrial involvement, primary tumor size ≤4 cm, cervical stromal invasion <1/2 and without lymph-vascular space invasion) cervical cancer patients own a more favorable outcome, with a 96% 5-year overall survival rate (4). However, relapse will develop in about 16% of patients after primary radical surgery (5, 6) , the overall recurrence rate can be up to 11% even if in Stage IA2-IB1 (7) , and the prognosis of patients with recurrent cervical cancer is still extremely poor (8) .
Currently, most patients with FIGO Stage IB1-IIA cervical cancer are treated with radical hysterectomy and pelvic lymph node dissection, since surgery can offer some prognosis-related pathological findings, including high-risk factors (pelvic lymph node metastasis, parametrial involvement, positive surgical margin) and intermediate risk factors (primary tumor size >4 cm, cervical stromal invasion ≥1/2, lymph-vascular space invasion). NCCN guidelines of cervical cancer recommend that patients with high-risk factors should accept postoperative concurrent chemoradiation (CCRT), and also vaginal brachytherapy if surgical margin is positive, and postoperative radiotherapy (RT) alone or CCRT or observed for patients with intermediate risk factors (9) . For a long time, no standard criteria are available to define tumor diameter and cervical stromal infiltration depth as intermediate risk factors, we always consider primary tumor size >4 cm, cervical stromal invasion ≥1/2 as intermediate risk factors. Several studies also put primary tumor size >2 cm, cervical stromal invasion ≥1/3 into this coverage, but patients received postoperative adjuvant therapy were the one with two or more intermediate risk factors. For example, a study found that the patients received RT included 89% of patients with tumors ≥2 cm and lymph-vascular space invasion, 76% of patients with tumors ≥2 cm and depth of invasion >10 mm and 87% of patients with tumors depth of invasion >10 mm and lymph-vascular space invasion (10).
Patients without above risk factors belong to low-risk type, whether these patients need adjuvant therapy and its indications and ways is still exploring. Since postoperative adjuvant RT can bring the survival benefit for patients with high or intermediate risk factors from, we believe it can also improve the prognosis of low-risk patients (11) (12) (13) . At present we mainly adopt empirical treatment, including RT and chemotherapy (CT) or both. Currently, there were no publications about adjuvant pelvic RT postoperatively in cervical cancer with low-risk factors.
Here we report the treatment results among early-stage cervical cancer patients with low-risk factors receiving adjuvant RT or CT in our institution, all of whom were treated initially by radical hysterectomy and pelvic lymph node dissection, and also aim to find the prognosis-related factors.
Materials and methods

Patients
Between June 2003 and April 2011, 267 FIGO Stage IB1-IIA cervical cancer patients with low-risk factors who underwent primary surgical treatment at Zhongnan Hospital of Wuhan University (Wuhan China) were reviewed. To be eligible, patients had to fulfill the following criteria: age of 18-75 years old, histologically confirmed cervical cancer, clinically diagnosed as Stage IB1-IIA disease according to FIGO staging system, treated with radical hysterectomy (Piver-Rutledge Class III, it includes the removal of the uterus, the upper third of the vagina, the paravaginal and parametrial tissues.) and pelvic lymph node dissection (including all nodal tissue from the common iliac, internal and external iliac, obturator and sacroanterior) primarily, pathological findings: negative pelvic lymph nodes and surgical margin, without parametrial involvement, primary tumor size ≤4 cm, cervical stromal invasion <1/2, and without lymph-vascular space invasion, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, adequate hematopoietic function (white blood cell count ≥3.5 × 10 9 /l, hemoglobin ≥100 g/l). Patients who accepted neoadjuvant chemotherapy (n = 35) or were out of touch after surgery (n = 7) were excluded. Thus, a total of 225 patients were available for analysis. This retrospective study was approved by the Ethics Committee of Zhongnan hospital.
Radiotherapy
Of the 225 patients, 117 (52%) received a course of pelvic external irradiation following radical surgery. Adjuvant RT was started within 2-3 weeks after radical surgery. Postoperative RT mainly implemented on the patients who had experienced ovarian transposition or whose ovarian function has been degraded, or patients have the willing. Pelvic RT was delivered with 15 MV X-rays and mainly by a four-field box technique. No patients accepted vaginal brachytherapy. RT was given to the pelvis, the upper limit being placed at the intervertebral level between L4 and L5, and the inferior limit at the inferior border of the obturator. The clinical target volume (CTV) encompassed the surgical stump, as well as the surrounding soft tissue and pelvic lymph node regions such as the common iliac, internal and external iliac, obturator and sacroanterior. The median radiation dose to the whole pelvis was 46 Gy (range from 40 to 50 Gy). Each patient was to be given daily fraction of 2.0 Gy within 4-5 weeks (five fractions weekly).
Chemotherapy
Twenty-five percent (57/225) patients received adjuvant CT after radical surgery. The patients in the RT group usually implemented CT before RT. The CT regimens were platinum-based therapy given 
Follow up
During postoperative RT, complete blood cell count was performed weekly, renal and liver function and urinalysis every two weeks. After completing the treatment, patients were followed up regularly by policlinic or telephone, about once every 3 months for 2 years and every 6 months the next 3 years and once a year 5 years later. The review includes the physical examination of the body and gynecology, serum squamous cell carcinoma antigen, papanicolaou smear, pelvic and abdominal ultrasonic test and chest radiography or pelvic magnetic resonance imaging and chest and abdominal computed tomography, or PET/CT when necessary. The date of last follow up was April 2016.
Statistics
Overall survival (OS) was defined from the beginning of radical surgery to the time of death due to any cause or last follow-up. Disease-free survival (DFS) was defined from the beginning of radical surgery to the time of tumor progression or last follow-up. Local regional disease-free survival (LRDFS) was defined from the beginning of radical surgery to the time of local regional progression or last follow-up. Distant metastasis-free survival (DMFS) was defined from the beginning of radical surgery to the time of appearance of metastatic disease or last follow-up. The Pearson χ 2 test was used to compare the baseline characteristics. Survival analysis was performed using the Kaplan-Meier method and log-rank test. Univariate survival analyses were performed with a Coxproportional hazards model to evaluate potential prognostic factors for OS and DFS. A statistically significant difference was defined as P < 0.05. All data were processed with SPSS version 21.0.
Results
Clinicopathologic characteristics
A total of 225 Stage IB1-IIA cervical cancer patients with low-risk factors were enrolled in this study. The median age was 47 years (range, . Of all 225 patients, 117 (52%) received postoperative adjuvant pelvic RT. The demographic and clinicopathologic characteristics of patients were compared according to with or without pelvic RT ( 
Pattern of failure and cause of death
The median follow up was 73 months (6-123 months), the followup rate was 81.8% for 5-year. The 5-year OS of 225 patients was 91.2%, and 5-year DFS was 84.5% (Fig. 1) . Up to the last day of follow-up, among the patients with RT, six patients (5.13%) developed relapse, four patients (3.42%) developed distant metastases, and eight patients (6.84%) developed death. Among the patients with non-RT, 20 patients (18.5%) developed relapse, two patients (1.85%) developed distant metastases, one patient developed both relapse and distant metastases, 11 patients (10.2%) developed death. The majority of deaths were attributed to cervical cancer and only one patient died of kidney failure caused by diabetes (Table 2) . Patients who developed lung metastases usually died in about 1 year after confirming. One patient suffered lung metastases 4 years after radical surgery has been continued to live for 53 months by local RT.
Treatment outcomes
Patients in the RT group achieved significant DFS and LRDFS prolongation compared with those in the non-RT group (5-year DFS, 91.2% vs. 77.1%, P = 0.006; 5-year LRDFS 94.6% vs. 79.0%, P = 0.001; Fig. 2 ). There were no statistically significant differences in the 5-year OS (92.9% vs. 89.4%, P = 0.371) and DMFS (96.4% vs. 96.5%, P = 0.887) between the patients with RT and the patients without (Fig. 2) . Subgroup analysis shows the 5-year DFS of RT alone, CT alone, non-RT/CT, RT and CT were 90.5%, 62.9%, 81.4%, 92.5% separately (P = 0.002). The 5-year OS was not significantly different (91.6% vs. 78.2% vs. 92.9% vs. 96.9%, P = 0.887) between the four groups (Fig. 3) .
Toxicity reactions
No fatal toxicity reaction occurred to the patients during the RT phase. Acute Grade 1-2 toxicity reactions on all patients in the RT group included anemia, neutrocytopenia, thrombocytopenia, diarrhea, genitourinary and lymphatic adverse effect. In patients receiving RT, one patient experienced Grade 4 neutrocytopenia, one patient experienced Grade 3 anemia and two patients had Grade 3-4 diarrhea (P > 0.05). All the Grade 3-4 hemotologic and gastrointestinal toxicities were transient and tolerable with supportive treatment. At regular follow-up visits, only one late radiationrelated toxicity (Grade 3) occurred in large intestine.
Prognostic analysis
Univariate analysis by Cox-proportional hazards model for DFS and OS in Stage IB1-IIA cervical cancer patients with low-risk factors is shown in Table 3 . The RT alone and 'RT and CT' groups showed longer DFS compared with the Non-RT/CT group, but not significant. The result also showed postoperative CT was the only significant risk factor for DFS (RT alone/CT alone, 'Non-RT/CT'/ CT alone, RT and CT/CT alone: Hazard ratio (HR), 0.216, 0.416, 
Discussion
During last two decades, the practice of treating the cervical cancer had changed significantly. More and more attention was paid to the comprehensive and individualized treatment, but there were still some debates. With regard to adjuvant treatment postoperatively, the result of Southwest Oncology Group (SWOG) 87-97 revealed that the addition of concurrent cisplatin-based CCRT significantly improved progression-free survival (PFS) and OS for high-risk, early-stage patients who undergo radical surgery for carcinoma of the cervix (11) . For patients with intermediate risk factors, two GOG prospective randomized clinical trials has already shown that adjuvant RT reduced the risk of recurrence by 47% (relative risk = 0.53, P = 0.008) and the risk of progression or death (hazard ratio=0.58, P = 0.009) (12, 13) . Two another retrospective studies compared the prognostic difference of CCRT plus RT alone in patients with intermediate risk factors. Kim et al. (14) showed that the recurrence-free survival (RFS) rate of the CCRT group was significantly higher than that of the RT group (P = 0.01). The estimated 5-year RFS rate of the CCRT group was 89% and that of the RT group was 67%. Ryu et al. (15) reported the result was not ideal, the difference between the RT and CCRT group was marginal in terms of the 3-year RFS (P = 0.09), they put primary tumor size ≥2 cm in the study, but all recurrences occurred in those who had at least two intermediate risk factors. Some experts believe that CT alone is also a worth considering method for patients with intermediate risk factors who need to preserve ovarian function. Wen et al. (16) found that whether patients with high-risk factors or intermediate-risk factors, the 5-year OS and 3-year DFS had no difference between CT and CCRT or RT groups respectively.
Whether cervical cancer patients with low-risk factors need to receive postoperative therapy still remains to be established. NCCN guidelines did not mention the adjuvant therapy for this kind of patients. Postoperative adjuvant therapy for cervical cancer with low-risk factors did not appear in the GOG etc. large clinical trials. Kundargi et al. (17) reported the 5-year event-free survival was 86.5% in those from the low-risk group received no further treatment after radical operation, significantly better than 73% in those from the intermediate-risk group accepted postoperative RT. What's more, if patients accept RT postoperatively immediately, they may lose the opportunity of the potential use of RT when recurrence. Patients with central or lateral pelvic failure after surgery alone can be treated with concurrent cisplatin-based chemoradiation, whereas pelvic exenteration usually represents the only therapeutic option with curative intent for women with central pelvic relapse who have previously received irradiation (18) . Nowadays, with the continuous development of radiation technology, especially RT has achieved an effectiveness of approximate surgery in early-stage cervical cancer. What's more, subclinical lesions may be escaped from the pathological detection after surgery. Postoperative pelvic RT is equivalent to a more thorough resection to pelvic lesions. The efficacy of adjuvant RT has been widely accepted after patients with high and intermediate risk factors acquired significant survival advantages from it. Between 1970 and 2007, mortality and recurrence rate of women receiving postoperative RT for early-stage cervical cancer was reduced by more than half (from OR = 2.2 to OR = 0.9) (19). Despite adjuvant RT in patients with low-risk factors did not get the recommendation from NCCN guidelines, many oncologists still attempt to deliver RT for this kind of patients after operation in routine clinical practice. With radiation equipment constantly updating and more strict quality control, especially with the emergence of intensity-modulated radiotherapy (IMRT) recent years, complications brought by RT were moderate and can be relieved by supporting treatment. Forrest et al. (20) reported that IMRT was associated with a significant reduction in the dose to organs at risk at the V50, V45, V40 and V30 level.
There was a >20% difference in V50 in most patients: 84% (bladder), 58% (small bowel), 54% (sigmoid) and 84% (rectum). Our data revealed adjuvant RT did not significantly increase Grade 3-4 treatment-related acute toxicities compared with non-RT. And also IMRT has gradually been applied to cervical cancer for adjuvant therapy in our institute, so the toxicities should be lower. To our knowledge, we first compared postoperative RT with non-RT in low-risk Stage IB1-IIA cervical cancer. In our series, postoperative RT can prolong the DFS compared with non-RT, without increased treatment-related Grade 3-4 acute and late toxicities, the 5-year DFS was 91.2% vs. 77.1%, respectively. But no OS difference was found between two groups, the 5-year OS was 92.9% and 89.4%, respectively. The result was consistent with a Phase III randomized trial (13) which found that the RT arm showed a statistically significant reduction in risk of progression compared with non-RT (5-year PFS, 81% vs. 69%, P = 0.009), but the improvement in OS with RT did not reach statistical significance (5-year OS, 85% vs. 77%, P = 0.074). Our result was also supported by a metaanalysis (21) , which showed that no significant difference in survival at 5 years between women who received radiation and those who received no further treatment (risk ratio (RR) = 0.8; 95% CI 0.3-2.4). However, women who received radiation had a significantly lower risk of disease progression at 5 years (RR = 0.6; 95% CI 0.4-0.9), and the risk of serious adverse events was not statistically significant. But some experts hold a different view, a study by Ayhan et al. (22) showed that the DFS, recurrence rate and site did not differ between patients underwent radical surgery and radical surgery plus RT, but with increased Grade 3-4 complications significantly (11.6% vs. 2.5%, P < 0.05). Likewise, when we perform subgroup analysis, the results suggest that the RT alone and 'RT and CT' groups can also get longer DFS compared with the Non-RT/CT group in low-risk Stage IB1-IIA cervical cancer, but no longer significant. If we extend the follow-up time and expand the sample size, a valuable survival result may be obtained. This needs us to carry out standardization system of follow-up and strengthen the comprehensive measures of various kinds of follow-up to increase the rate. And we would better develop multicenter cooperation. Our study also suggested that postoperative RT may lead to significant LRDFS benefit, the 5-year LRDFS was 94.6% vs. 79.0% respectively. However, the DMFS was not significantly different between the two groups. Our data found that 33 patients suffered recurrence. Of which 26 were in the local region, 20 (18.5%) patients with local recurrence were from the non-RT group, much higher than that (5.13%) in the RT group. Distant metastasis was not different between two groups. The inspiring result demonstrates that adjuvant RT helps to reduce recurrence and improve loco-regional control, but the effectiveness of controlling distant metastasis was not obvious. Kukura et al. (23) reported that the rate of locoregional recurrences was 12.8% in low-risk cervical cancer without further treatment after radical surgery, the rate was also much higher than that in the patients who received adjuvant RT in our result. While Rotman et al. (13) reported that both local (13.9% vs. 20.7%) and distal (2.9% vs. 8.6%) recurrence rates were lower in RT compared with non-RT. Our results found that the addition of CT after surgery is harmful to DFS. It may result from the insufficient course of CT, patients accepted only one course of CT accounted for 54%. This result was worse than a retrospective study that showed among the histologic Grade III patients, no significant differences was found in the OS (97.0% vs. 95.0%) or tumor recurrence (4.0% vs. 4.7%) between the patients with adjuvant CT and those without (P > 0.05) (4). There was a contradiction between the results of Fig. 2 and Table 3 , the former showed that the adjuvant RT could prolong the DFS time significantly, but the latter subgroup univariate analysis showed there was just a tendency, but not significant. Why? we analyze the reasons are as follows: the RT group included 'RT alone' and 'RT and CT' subgroups, and the CT can increase the sensitivity of RT, then enhanced the effect of RT group on DFS; Non-RT group included 'CT alone' and 'non-RT/CT' subgroups, CT alone was harmful to survival, then further reduce the DFS of non-RT group.
In summary, our results suggest that Stage IB1-IIA carcinoma of uterine cervix with low-risk factors has a favorable prognosis after radical surgery. Non-standard CT is harmful to the prognosis (DFS) of these patients. Although postoperative adjuvant pelvic RT can not prolong the DFS time significantly, about 10% of the patients can still benefit from it. It can reduce local recurrence remarkably, but the effectiveness of controlling distant metastasis was not obvious. Due to this kind of patients can live for a long time, we need to increase the follow-up time to clear whether postoperative adjuvant RT is beneficial to long-term survival.
